TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer
Helsinki, Finland – 26th September 2022: TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces it has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy.
